Cytori Therapeutics (NASDAQ:CYTX) received a $5.00 target price from equities research analysts at Maxim Group in a note issued to investors on Friday. The brokerage presently has a “buy” rating on the biotechnology company’s stock.

A number of other brokerages have also issued reports on CYTX. Zacks Investment Research raised shares of Cytori Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. B. Riley reaffirmed a “hold” rating on shares of Cytori Therapeutics in a report on Tuesday, November 7th.

Shares of Cytori Therapeutics (NASDAQ CYTX) traded up $0.20 during trading hours on Friday, hitting $0.47. 7,677,959 shares of the stock traded hands, compared to its average volume of 2,638,175. Cytori Therapeutics has a 52-week low of $0.22 and a 52-week high of $2.13. The company has a market cap of $16.51, a PE ratio of -0.52 and a beta of 3.21.

Cytori Therapeutics (NASDAQ:CYTX) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. Cytori Therapeutics had a negative net margin of 367.33% and a negative return on equity of 228.21%. The company had revenue of $1.77 million for the quarter, compared to analysts’ expectations of $2.04 million. During the same quarter last year, the business earned ($0.26) EPS. sell-side analysts anticipate that Cytori Therapeutics will post -0.62 earnings per share for the current year.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Sabby Management LLC raised its holdings in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 28.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,626,807 shares of the biotechnology company’s stock after purchasing an additional 355,504 shares during the quarter. Sabby Management LLC owned 4.69% of Cytori Therapeutics worth $1,789,000 at the end of the most recent reporting period. Institutional investors own 7.41% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Cytori Therapeutics (CYTX) Given a $5.00 Price Target by Maxim Group Analysts” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2018/01/05/cytori-therapeutics-cytx-given-a-5-00-price-target-by-maxim-group-analysts.html.

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.